1. Age over 18 years. 2. Diagnosed with low-grade glioma based on clinical standard of care imaging and
scheduled for primary surgical resection of low-grade glioma. 3. Females of childbearing potential and males agree to use an effective method of
contraception from the time consent is signed until 1 week after surgery.
4. Females of childbearing potential have a negative urine pregnancy test within 7 days
prior to being registered. Participants are considered not of child bearing potential
if they are surgically sterile (i.e. they have undergone a hysterectomy, bilateral
tubal ligation, or bilateral oophorectomy) or they are postmenopausal. 5. Willing and able to provide written informed consent.
1. Females who are pregnant, planning pregnancy or breastfeeding. 2. Concurrent and/or recent involvement in other research or use of another experimental
investigational medicinal product that is likely to interfere with the study
medication within 28 days of study enrolment.
3. MRI contraindicated (e.g. implanted electric and electronic devices, heart pacemakers,
insulin pumps, implanted hearing aids, neurostimulators, intracranial metal clips,
metallic bodies in the eye).
4. Other psychological, social or medical condition, physical examination finding or a
laboratory abnormality that the Investigator considers would make the patient a poor
study candidate or could interfere with protocol compliance or the interpretation of
5. Neoadjuvant chemotherapy/radiotherapy treatment for low-grade glioma which would
interfere with the interpretation of study results.
6. Any other problems that may make the patient unable to tolerate the PET scans (e.g.